TerminatedNot applicableNCT01451489
The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis
Studying Hereditary steroid-resistant nephrotic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nanjing University School of Medicine
- Principal Investigator
- Zhihong Liu, MD, M.DResearch Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine
- Intervention
- FK506(drug)
- Enrollment
- 70 target
- Eligibility
- 14-65 years · All sexes
- Timeline
- 2011 – 2016
Study locations (1)
- Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01451489 on ClinicalTrials.govOther trials for Hereditary steroid-resistant nephrotic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06635720REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)The Hospital for Sick Children
- RECRUITINGNCT06334692Autoantibodies Against-nephrin in Idiopathic Nephrotic SyndromeMario Negri Institute for Pharmacological Research
- RECRUITINGNCT06162546ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and BiobankChristoph Aufricht
- RECRUITINGPHASE3NCT05183646A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARBDimerix Bioscience Pty Ltd
- RECRUITINGNCT01605266INSIGHT (Insight Into Nephrotic Syndrome)The Hospital for Sick Children
See all trials for Hereditary steroid-resistant nephrotic syndrome →